CDXS
What one share of Codexis holds
Industrial Organic Chemicals
We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by using our proprietary CodeEvolver® directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins.
Codexis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.86 |
|---|---|
| Profit | −$0.34 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.13 |
| Cash and investments | $0.30 |
| Debt | $0.45 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.20 | −$0.21 | $0.02 | −$0.07 | — | $0.46 |
| 2017 | $1.08 | −$0.50 | $0.02 | −$0.21 | — | $0.51 |
| 2018 | $1.16 | −$0.21 | $0.05 | −$0.32 | — | $1.04 |
| 2019 | $1.21 | −$0.21 | $0.07 | −$0.29 | — | $1.79 |
| 2020 | $1.16 | −$0.40 | $0.06 | −$0.34 | — | $2.65 |
| 2021 | $1.62 | −$0.33 | $0.21 | −$0.44 | — | $2.52 |
| 2022 | $2.12 | −$0.51 | $0.13 | $0.05 | — | $2.20 |
| 2023 | $1.03 | −$1.12 | $0.06 | −$0.84 | — | $1.24 |
| 2024 | $0.81 | −$0.89 | $0.06 | −$0.73 | — | $0.82 |
| 2025 | $0.81 | −$0.50 | $0.05 | −$0.27 | — | $0.56 |